Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases

Area of Science:

• Rheumatology
• Clinical Pharmacology

Background:

• Standard randomized controlled trials (RCTs) may not detect potential advantages of combination second-line drug therapy in rheumatoid arthritis (RA).
• Limitations in RCTs include short time frames, specific patient selection, and insufficient patient numbers.
• These limitations can render it difficult to document the efficacy of combination therapy in RA.

Purpose of the Study:

• To explore the limitations of standard clinical trials in detecting the benefits of combination second-line drug therapy for rheumatoid arthritis (RA).
• To illustrate how study design can impact the perceived efficacy of treatments in rheumatic diseases.

Main Methods:

• Analysis of clinical trial limitations in rheumatic diseases, including systemic lupus erythematosus and rheumatoid arthritis.
• Comparison of data from standard RCTs with long-term clinical trials, pooled analyses, and longitudinal databases.
• Examination of a subset of RA data mimicking RCT conditions to assess treatment continuation rates.

Main Results:

• Well-designed RCTs comparing drug combinations with monotherapy in systemic lupus erythematosus were often inconclusive.
• Long-term studies and databases showed superiority of combination therapy where RCTs did not.
• In RA, a 48-week study found no difference between auranofin, methotrexate, or their combination, contrasting with longer-term database observations.

Conclusions:

• Intrinsic limitations of standard RCTs, such as patient selection and short durations, may obscure the true efficacy of combination second-line drug therapy in RA.
• Longitudinal data and pooled analyses may provide a more accurate assessment of long-term treatment benefits in rheumatic diseases.
• Further research may be needed to refine trial designs for evaluating complex therapeutic strategies in RA.